MPS Powered by Eureka

Current Cancer Therapy Reviews

ISSN: 1573-3947 (Print)
eISSN: 1875-6301 (Online)

Journal
Impact Factor :

0.4

Scopus
CiteScore:

1

Aims and Scope:Current Cancer Therapy Reviews publishes full-length review/mini-reviews, original research articles, drug clinical trial studies and guest-edited thematic issues on all the latest advances in clinical oncology, cancer therapy and pharmacology. The journal aims to publish the highest quality review articles dedicated to clinical research in the field. The journal is essential reading for all researchers and clinicians in the field of cancer therapy. It covers papers related to prevention, diagnosis and treatment of all types of cancers through biomarkers testing, biopsy, chemotherapy, hormone therapy, gene therapy, hyperthermia, immunotherapy, irreversible electroporation, laser therapy, photodynamic therapy, radiation therapy, radiotherapy and stem cell transplantation.

Editor-in-Chief:


Yangchao Chen School of Biomedical Sciences
Faculty of Medicine
The Chinese University of Hong Kong
Shatin
Hong Kong

Indexed in:


Scopus, Scopus, ESCI... View all

Special Issues With Active Call for Papers

Submission closes on: Dec 31, 2025
Advancements in Lipid Nanoparticle Delivery Systems for mRNA Therapeutics

The thematic issue "Advancements in Lipid Nanoparticle Delivery Systems for mRNA Therapeutics" aims to explore cutting-edge developments and innovative strategies in the field of lipid nanoparticle (LNP) technology, particularly focusing on its application in mRNA delivery. This topic has gained unprecedented attention and urgency in the wake of the COVID-19 pandemic, where LNP-based mRNA vaccines have demonstrated immense potential and efficacy. The scope of this issue encompasses a broad range of topics including the design... see more

Submission closes on: Dec 31, 2025
Current Progress in Protein Degradation and Cancer Therapy

Targeted Protein Degradation is gaining momentum in cancer therapy; it facilitates targeting undruggable proteins, overcomes cancer resistance, and avoids undesirable side effects. Thus small molecule degraders have emerged as novel therapeutic strategies. Targeted protein degradation (TPD), the process of eliminating a protein of interest holds a great promise for the development of cancer therapy. The main focus of TPD is the development of heterobifunctional small molecules degraders, including proteolysis-targeting chimeras (PROTACs), which contain two linked... see more